title: Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer.
abstract: We previously reported that novel targeted "hybrid peptide" in which epidermal growth factor receptor (EGFR) binding peptide was conjugated with lytic-type peptide had selective cytotoxic activity to EGFR expressing cancer cells. In this study, we have generated a novel type hybrid peptide, semaphorin 3A lytic (Sema3A-lytic), which is composed of two functional amino acid domains: a sequence derived from Sema3A that binds to neuropilin-1 (NRP1) and a cytotoxic lytic peptide. We found that this hybrid peptide had cytotoxic activity against NRP1-positive pancreatic cancer cell lines such as BxPC-3 and Panc-1, whereas the peptide did not affect the viability of normal cells in vitro. It was also found by affinity analysis that Sema3A peptide binds to NRP1, and two arginines (372R and 377R) in Sema3A peptide are involved in the interaction with NRP1 protein. In addition, confocal microscopy analysis revealed that Sema3A-lytic peptide could not penetrate normal cells regardless of the presence of NRP1 mRNA, suggesting that the ability of Sema3A-lytic peptide to concentrate adjacent to the cell membrane by binding to NRP1 with the target-binding moiety contributes to its selective cytotoxic activity. These results indicate that Sema3A-lytic hybrid peptide would be a possible anti-cancer agent for treatment of human pancreatic cancer.
authors.affiliation: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.
authors.forename: Hanae
authors.initials: H
authors.lastname: Ueyama
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Horibe
authors.forename: Oumi
authors.initials: O
authors.lastname: Nakajima
authors.forename: Koji
authors.initials: K
authors.lastname: Ohara
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kohno
authors.forename: Koji
authors.initials: K
authors.lastname: Kawakami
mesh_terms: D000595:Amino Acid Sequence; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D006801:Humans; D008969:Molecular Sequence Data; D039942:Neuropilin-1 / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000378:metabolism*; D010455:Peptides / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D011993:Recombinant Fusion Proteins / Q000378:metabolism* / Q000494:pharmacology; D040121:Semaphorin-3A / Q000378:metabolism / Q000494:pharmacology; D039961:Semaphorins / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D010455:Peptides; D011993:Recombinant Fusion Proteins; D040121:Semaphorin-3A; D039961:Semaphorins; C568476:semaphorin 3A lytic peptide; D039942:Neuropilin-1